Clinical Evaluation of Fluphenazine in Cases of Anxiety and Other Psychoneuroses

Abstract

Halogen substitution and introduction of a piperazine ring into the side chain of the chlorpromazine molecule resulted in a compound which is effective in small doses and thus appears to have reduced hypnotic potential and neurotoxicity.

Clinical studies indicate that fluphenazine produced clinically satisfactory improvement in the majority of patients suffering predominantly from anxiety; most of them were treated with only 0.5 mg. or less per day. Studies so far revealed minimal incidence of side effects.

Fluphenazine seems to be a potent psycho-pharmacologic agent in the clinic or office management of anxiety states and other psychoneuroses.